ABSTRACT
We herein report a case of Behçet's disease in a 27-year-old female who suffered from generalized skin rashes for one week. After hospitalization, massive bloody stools accompanying hypovolemic shock occurred. Emergency abdominal computed tomography-angiography failed to detect the bleeding source. Esophagogastroduodenoscopy also demonstrated no definite bleeding points. Ileocolonoscopy showed multiple large and deep ulcers with some blood coating and mild oozing in the terminal ileum. We initially performed epinephrine injection and hemoclips for her intestinal bleeding. However, massive bloody stools still continued. Thus, we prescribed a loading dose of 160 mg adalimumab followed by weekly 80 mg adalimumab subcutaneous injections to the patient. Following this treatment, her gastrointestinal bleeding gradually subsided and completely stopped within a few days. After three-week therapy with adalimumab, capsule endoscopy showed several healing ulcers without bleeding in the distal to the terminal ileum. She continues to be treated with adalimumab, azathioprine, and mesalazine without recurrent bleeding.
Subject(s)
Behcet Syndrome , Female , Humans , Adult , Adalimumab/therapeutic use , Behcet Syndrome/complications , Behcet Syndrome/drug therapy , Behcet Syndrome/diagnosis , Ulcer/complications , Ulcer/drug therapy , Gastrointestinal Hemorrhage/drug therapy , Gastrointestinal Hemorrhage/etiology , Ileum/diagnostic imagingABSTRACT
INTRODUCTION: Both cardiovascular diseases (CVD) and osteoporosis are common comorbidities in rheumatoid arthritis (RA) patients. Although accumulating evidence indicates a link between CVD and osteoporotic fracture, whether CVD contributes to osteoporotic fracture risk in RA has yet to be explored. We examined the incidence rate and risk factors of osteoporotic vertebral fracture in RA patients with new-onset CVD (RA-CVD) and evaluated the effects of medications on such fracture risk. METHODS: A retrospective study was conducted using a nationwide database from 2000 to 2010: 1267 RA-CVD and 1267 non-CVD patients were enrolled from 30,507 patients with newly diagnosed RA. The main outcome was the development of osteoporotic vertebral fracture. After being adjusted for age, gender, and comorbidities, the Cox proportional hazard model was used to identify independent factors contributing to osteoporotic vertebral fracture. RESULTS: The adjusted hazard ratio (aHR) of developing osteoporotic vertebral fracture was 1.47-fold greater in RA-CVD group than in non-CVD group (95% confidence interval 1.19-1.81, p < 0.001). Both the age above 40 years and female gender were significant risk factors for developing osteoporotic vertebral fracture in RA-CVD patients. Using patients not taking medication as a reference group, the aHR of osteoporotic vertebral fracture was significantly lower in those receiving statins (0.50), low-dose corticosteroids (0.57), or hydroxychloroquine (0.12). CONCLUSIONS: The risk of osteoporotic vertebral fracture was significantly increased in RA-CVD patients, particularly women above 40 years of age, and could be reduced by statin therapy. However, the protective effect of low-dose corticosteroids or hydroxychloroquine on osteoporotic vertebral fracture risk needs further validation.
Subject(s)
Arthritis, Rheumatoid/epidemiology , Cardiovascular Diseases/epidemiology , Osteoporotic Fractures/epidemiology , Adult , Aged , Arthritis, Rheumatoid/complications , Cardiovascular Diseases/complications , Comorbidity , Databases, Factual , Female , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Incidence , Kaplan-Meier Estimate , Male , Middle Aged , Osteoporotic Fractures/etiology , Osteoporotic Fractures/prevention & control , Retrospective Studies , Risk Assessment/methods , Risk Factors , Spinal Fractures/epidemiology , Spinal Fractures/etiology , Spinal Fractures/prevention & control , Taiwan/epidemiologyABSTRACT
BACKGROUND: The treatment of H. pylori-associated gastroduodenal disease is increasingly aimed at bacterial eradication which requires follow-up assessment of therapeutic effectiveness and re-infection. A simplified 37 kBq 14C-urea breath test for H. pylori infection has been developed. METHODS: The 37 kBq 14C-urea breath test was compared with biopsy urease (CLO) and histological analyses of gastric-biopsies obtained from 63 patients undergoing endoscopy. RESULTS: The 30-min breath test correlated closely with biopsy findings, had a sensitivity of 100%, a specificity of 95% and a positive predictive value of 92%. CONCLUSIONS: The simplified, low-dose, 14C-urea breath test is a convenient, low-cost, transportable means of facilitating the management of H. pylori-associated diseases.
